Fundamental mechanisms and implications of neuronal apoptosis

Neuronal Cell Apoptosis

Volumn , Issue , 2011, Pages 143-165

  Tharakan, Binu ^a   Chowdhury, Indrajit ^b   Bhat, Ganapathy ^b  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895407181     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (108)

1. Chowdhury I, Tharakan B, Bhat GK. Current concepts in apoptosis: the physiological suicide program revisited. Cell Mol. Biol. Lett, 11:506-25, 2006.
2. Yang JC, Cortopassi GA. Induction of the mitochondrial permeability transition causes release of the apoptogenic factor Cytochromec. Free Radic. Biol. Med, 24:624-631, 1998.
3. Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene, 23:2861-74, 2004.
4. Jiang X, Wang X. Cytochromec promotes caspase-9 activation by inducing nucleotide binding to Apaf-1. J. Biol. Chem, 275:31199-31203, 2000.
5. Chowdhury I, Tharakan B, Bhat GK. Caspases -an update. Comp. Biochem. Physiol. B Biochem. Mol. Biol, 151:10-27, 2008.
6. Krantic S, MechawarN, Reix S, Quirion R. Apoptosis-inducing factor: A matter of neuron life and death. Progress in Neurobiology, 81: 179-196, 2007.
7. Okouchi M, Ekshyyan O, Maracine M, Aw TY. Neuronal apoptosis in neurodegeneration. Antioxidant and Redox Signaling, 9: 1059-1096, 2007
8. Robertson JD, Orrenius S, Zhivotovsky B. Review: nuclear events in apoptosis. J. Struct. Biol, 129: 346-358, 2000.
9. Deveraux QL, Takahashi R, Salvesen GS, Reed GC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature, 388: 300-304, 1997.
10. Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K, Takahashi R. A serine protease, Htra2, is release from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell, 8: 613-621, 2001.
11. Van Gurp M, Festjens N, van Loo G, Saelens X, Vandenabeele P. Mitochondrial intermembrane proteins in cell death. Biochem. Biophys. Res. Commun, 304: 487-497, 2003.
12. Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi N, Bernard A, Mermod JJ, Mazzei G, Maundrell K, Gambale F, Sadoul R, Martinou JC. Inhibition of Bax channel-forming activity by Bcl-2. Science, 277: 370-372, 1997.
13. Keinan N, Tyomkin D, Shoshan-Barmatz V. Oligomerization of the mitochondrial protein voltage-dependent anion channel is coupled to the induction of apoptosis. Mol. Cell Biol, 30:5698-709, 2010.
14. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene, 22: 8543-8567, 2003.
15. Nagata S. Apoptosis by death factor. Cell, 88: 355-365, 1997.
16. Ashkenazi A. Targeting death and decoy receptors of the tumornecrosis factor superfamily. Natl. Rev. Cancer, 2: 420-430, 2002.
17. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science, 277: 818-821, 1997.
18. Peter ME, Krammer PH. The CD95 (APO-1/Fas) DISC and beyond. Cell Death Differ, 10: 26-35, 2003.
19. Li S, Zhao H, He X, Kim TH, Kuharsky DK, Rabinowich H, Chen J, Du C, Yin XM. Relief of extrinsic pathway inhibition by the Bid-dependent mitochondrial release of Smac in Fas-mediated hepatocyt apoptosis. J. Biol. Chem, 277: 26912-26920, 2002.
20. Raoul C, Henderson CE, Pettmann B. Programmed Cell death of embryonic motoneurons triggered through the Fas death receptor. J. Cell Biol, 29: 1049-1061, 1999.
21. Zuliani C, Kleber S, Klussmann S, Wenger T, Kenzelmann M, Schreglmall N, Martinez A, Del Rio JA, Soriano E, Vodrazka P, Kuner R, Groene Hj, Herr I, Krammer PH, Martin-Villarba A. Control of neuronal branching by the death receptor CD95 (Fas/APO-1). Cell Death Differ, 13: 31-40, 2006.
22. Li Y, Ji A, Weihe E, Schafer M. Cell-specific expression and lipoplysaccharide-induced regulation of tumor necrosis factor á (TNF-á) and TNF receptors in rat dorsal root ganglion. J. Neurosci, 24: 9623-9631, 2004.
23. Veglianese P, Lo Coco D, Bao Cutrona M, Magnoni R, Pennachini D, Pozzi B, Gowing G, Julien JP, Tortarolo M, Bendotti C. Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS. Mol. Cell Neurosci, 31: 218-231, 2006.
24. Dopp JM, Mackenzie-Graham A, Otero GC, Merrill JE. Differential expression, cytokine modulation, and specific functions of type-1 and type-2 of tumor necrosis factor receptors in rat glia. J. Immunol, 75: 104-112, 1997.
25. Figiel I, Dzwonek K. TNF_and TNF receptor 1 expression in the mixed neuronal-glial culturesof hippocampal dentate gyrus exposed to glutamate or trimethyltin. Brain Res, 1131: 17-28, 2007.
26. Dorr J, Bechmann I, Waiczies S, Aktas O, Walczak H, Krammer PH, Nitsch R, Zipp F. Lack of tumor necrosis factor-related apoptosis inducing ligand but presence of its receptors in the the human brain. J. Neurosci, 22: 1-5, 2002.
27. Spierings DC, De Vries EG, Vellenga E, Van den Heuvel F, Koornstra JJ, Wesseling J, Hollema H, de Jong S. Tissue distribution of the death ligand TRAIL and its receptors. J. Histoche Cytochem, 52: 821-831, 2004.
28. Burton TR, Dibrov A, Kashour T, Amara FM. Anti-apoptotic wild-type Alzheimer amyloid precursor protein signaling involves the p38 mitogen-activated protein kinase/MEF2 pathway. Brain Res. Mol. Brain Res, 108: 102-120, 2002.
29. Kim SK, Park HJ, Hong HS, Baik EJ, Jung MW, Mook-Jung I. ERK1/2 is an endogenous negative regulator of the gamma-secretase activity. FASEB J, 20: 157-159, 2006.
30. Klivenyi P, St Clair D, Wermer M, Yen HC, Oberley T, Yang L, Flint Beal M. Manganese superoxide dismutase. Neurobiol. Dis, 5: 253-258, 1998.
31. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell, 116: 205-219, 2004.
32. Culmsee, C., Zhu, C., Landshamer, S., Becattini, B., Wagner, E., Pellecchia, M., Blomgren, K., Plesnila, N. Apoptosis-inducing factor triggered by poly(ADP-ribose) polymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia. J. Neurosci, 25, 10262-10272, 2005.
33. Bulat N, Widmann C. Caspase substrates and neurodegenerative diseases. Brain Research Bulletin, 80: 251-267, 2009.
34. Oberst A, Bender C, Green DR. Living with death: the evolution of the mitochondrial pathway of apoptosis in animals. Cell Death Differ, 15: 1139-1146, 2008.
35. Nicholson DW, Thornberry, NA. Caspases: killer proteases. Trends Biochem. Sci, 22:299-306, 1997.
36. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis, Mol Cell, 9:459-470, 2002.
37. Siegel RM. Caspases at the crossroads of immune-cell life and death. Nat. Rev. Immunol, 6: 308-317, 308-317, 2006.
38. Yi CH, Yuan J. The Jekyll and Hyde functions of caspases. Dev. Cell, 16: 21-34, 2009.
39. Li ZG, Zhang W, Sima AA. C-peptide enhances insulin-mediated cell growth and protection against high glucose-induced apoptosis in SH-SY5Y cells. Diabetes Metab. Res. Rev, 19: 375-385, 2003.
40. Abraham MC, Shaham S. Death without caspases, caspases without death. Trends Cell Biol, 14, 184-193, 2004.
41. Algeciras-Schimnich A, Barnhart BC, Peter ME. Apoptosis-independent functions of killer caspases. Curr. Opin. Cell Biol, 14: 721-726, 2002.
42. Launay S, Hermine O, Fontenay M, Kroemer G, Solary E, Garrido C. Vital functions for lethal caspases. Oncogene, 24: 5137-5148, 2005.
43. Yang J.-Y, Michod D, Walicki J, Widmann C. Surviving the kiss of death. Biochem. Pharmacol, 68: 1027-1031, 2004.
44. Yi CH, Yuan J. The Jekyll and Hyde functions of caspases. Dev. Cell, 16: 21-34, 2009.
45. Huesmann GR, Clayton DF. Dynamic role of postsynaptic caspase-3 and finch BIRC4 in zebra song-response habituation. Neuron, 52:1067-1072, 2006.
46. Li Z, Jo J, Jia JM, Lo SC, Whitcomb DJ, Jiao S, Cho K, Sheng M. Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. Cell, 28: 141: 859-871, 2010.
47. Orrenius S. Reactive oxygen species in mitochondria-mediated cell death. Drug Metab. Rev, 39:443-55, 2007.
48. Constantini P, Belzacq AS, Vieira H, larochette N, de Pablo M, Zamzami N, Susin SA, Brenner C, Kroemer G. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene, 19: 307-314, 2000.
49. Ozawa T. Oxidative damage and fragmentation of mitochondrial DNA in cellular apoptosis. Biosci. Rep, 17: 237-250, 1997.
50. Ballinger SW, Patterson C, Yan CN, Doan R, Burow DL, Young CG, Yakes FM, Van Houten B, Ballinger CA, Freeman BA, Runge MS. Hydrogen peroxide-and peroxynitrite-induced mitochondrial. DNA damage and dysfunction in vascular endothelial and smooth muscle cells. Circ. Res, 86: 960-966, 2000.
51. Goldsmit Y, Erlich S, Pinkas-Kramarski R. Neuregulin induces sustained reactive oxygen species generation to mediate neuronal differentiation. Cell Mol. Neurobiol, 21: 753-769, 2001.
52. Golstein P, Kroemer G. Cell death by necrosis: towards a molecular definition. Trends Biochem. Sci. 32:37-43, 2007.
53. McCall K. Genetic control of necrosis -another type of programmed cell death. Curr. Opin. Cell Biol. 22:882-8, 2010.
54. Golstein, P., Aubry, L., Levraud, J.P. Cell-death alternative model organisms: why and which? Nat. Rev. Mol. Cell Biol, 4: 798-807, 2003.
55. Berman SB, Chen YB, Qi B, McCaffery JM, Rucker EB, Goebbels S, Nave KA, Arnold BA, Jonas EA, Pineda FJ, Hardwick JM. Bcl-x L increases mitochondrial fission, fusion, and biomass in neurons. J. Cell Biol, 184:707-719, 2009.
56. Cho DH, Nakamura T, Lipton SA. Mitochondrial dynamics in cell death and neurodegeneration. Cell Mol. Life Sci, 67:3435-47, 2010.
57. Chang CR, Blackstone C. Dynamic regulation of mitochondrial fission through modification of the dynamin-related protein Drp1. Ann. N. Y. Acad. Sci, 21201: 34-9, 2010.
58. Lu B. Mitochondrial dynamics and neurodegeneration. Current Neurol. Rep, 9:212-219, 2009.
59. Miller FD, Kaplan DR. Neurotrophin signalling pathways regulating neuronal apoptosis. Cell Mol. Life Sci, 58:1045-53, 2001.
60. Lossi L, Merighi A. In vivo cellular and molecular mechanisms of neuronal apoptosis in the mammalian CNS. Prog. Neurobiol, 69:287-312, 2003.
61. Jankowski J, Miething A, Schilling K, Baader SL. Physiological Purkinje cell death is spatiotemporally organized in the developing mouse cerebellum. Cerebellum, 8:277-290, 2009.
62. Wood KA, Dipasquale B, Youle RJ. In situ labeling of granule cells for apoptosis-associated DNA fragmentation reveals different mechanisms of cell loss in developing cerebellum. Neuron, 11: 621-632, 1993.
63. Krueger BK, Burne JF, Raff MC. Evidence for large-scale astrocyte death in the developing cerebellum. J. Neurosci. 15: 3366-3374, 1995.
64. Lossi L, Gambino G, Mioletti S, Merighi A. In vivo analysis reveals different apoptotic pathways in pre-and postmigratory cerebellar granule cells of rabbit. J. Neurobiol, 60: 437-452, 2004.
65. Lossi L, Zagzag D, Greco MA, Merighi A. Apoptosis of undifferentiated progenitors and granule cell precursors in the postnatal human cerebellar cortex correlates with expression of BCL-2, ICE, and Cpp32 proteins. J. Comp. Neurol, 399: 359-372, 1998.
66. Voiculescu B, Nat R, Lin E, Iosef C. Apoptosis in human embryo development: 1. Cerebral cortex. J. Cell Mol. Med, 4: 284-288, 2000.
67. Blaschke AJ, Staley K, Chun J. Widespread programmed cell death in proliferative and postmitotic regions of the fetal cerebral cortex. Development, 122:1165-74, 1996.
68. Thomaidou D, Mione MC, Cavanagh JF, Parnavelas JG. Apoptosis and its relation to the cell cycle in the developing cerebral cortex. J. Neurosci, 17:1075-85, 1997.
69. Yoshida H, Kong YY, Yoshida R, Elia AJ, Hakem A, Hakem R, Penninger JM, Mak TW. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell, 94: 739-750, 1998
70. Lossi L, Merighi, A. In vivo cellular and molecular mechanisms of neuronal apoptosis in the mammalian CNS. Prog. Neurobiol, 69: 287-312, 2003.
71. Jung JE, Kim GS, Chen H, Maier CM, Narasimhan P, Song YS, Niizuma K, Katsu M, Okami N, Yoshioka H, Sakata H, Goeders CE, Chan PH. Reperfusion and neurovascular dysfunction in stroke: from basic mechanisms to potential strategies for neuroprotection. Mol. Neurobiol, 41: 172-179, 2010.
72. Broughton BR, Reutens DC, Sobey CG. Apoptotic mechanisms after cerebral ischemia. Stroke, 40: e331-9, 2009.
73. Sims NR, Muyderman H. Mitochondria, oxidative metabolism and cell death in stroke. Biochim. Biophys. Acta, 1802: 80-91, 2010.
74. Wang X, Carlsson Y, Basso E, Zhu C, Rousset CI, Rasola A, Johansson BR, Blomgren K, Mallard C, Bernardi P, Forte MA, Hagberg H. Developmental shift of cyclophilin D contribution to hypoxic-ischemic brain injury. J. Neurosci, 29:2588-96, 2009.
75. Wang X, Han W, Du X, Zhu C, Carlsson Y, Mallard C, Jacotot E, Hagberg H. Neuroprotective effect of Bax-inhibiting peptide on neonatal brain injury. Stroke, 41:2050-2055, 2010.
76. Reich A, Spering C, Gertz K, Harms C, Gerhardt E, Kronenberg G, Nave KA, Schwab M, Tauber SC, Drinkut A, Harms K, Beier CP, Voigt A, Göbbels S, Endres M, Schulz JB. Fas/CD95 regulatory protein Faim2 is neuroprotective after transient brain ischemia. J. Neurosci, 31:225-33, 2011.
77. Wong J, Hoe NW, Zhiwei F, Ng I. Apoptosis and traumatic brain injury. Neurocrit. Care, 3:177-82, 2005.
78. Zhang X, Chen Y, Jenkins LW, Kochanek PM, Clark RS. Bench-to-bedside review: Apoptosis/programmed cell death triggered by traumatic brain injury. Crit. Care, 9:66-75, 2005.
79. Miñambres E, Ballesteros MA, Mayorga M, Marin MJ, Muñoz P, Figols J, López-Hoyos M. Cerebral apoptosis n severe traumatic brain injury patients: an in vitro, in vivo, and postmortem study. J. Neurotrauma, 25:581-591, 2008.
80. Spillantini MG and Goedert M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann. N. Y. Acad. Sci. 920: 16-27, 2000.
81. Gasser T. Genetics of Parkinson's disease. Curr. Opin. Neurol, 18: 363-369, 2005.
82. Banerjee R, Beal MF, Thomas B. Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications. Trends Neurosci, 33:541-9, 2010.
83. Büeler H. Mitochondrial dynamics, cell death and the pathogenesis of Parkinson's disease. Apoptosis, 15:1336-53, 2010
84. Su JH, Deng G, Cotman CW. Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology. J. Neuropathol. Exp. Neurol, 56: 86-93, 1997.
85. Anderson AJ, Pike CJ, Cotman CW. Differential induction of immediate early gene proteins in cultured neurons by beta-amyloid (A beta): association of c-Jun with A beta-induced apoptosis. J. Neurochem, 65: 1487-1498, 1995.
86. Rohn TT, Rissman RA, Davis MC, Kim YE, Cotman CW, Head E. Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol. Dis, 11: 341-354, 2002.
87. Zhang Y, McLaughlin R, Goodyer C, LeBlanc A. Selective cytotoxicity of intracellular amyloid peptide1-42 through p53 and Bax in cultured primary human neurons. J. Cell Biol, 156: 519-529, 2002.
88. Lyras L, Cairns NJ, Jenner A, Jenner P, Halliwell B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J. Neurochem, 68: 2061-2069, 1997.
89. Lovell MA, Xie C, Markesbery WR. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology, 51: 1562-1566, 1998.
90. Marcus DL, Thomas C, Rodriguez C, Simberkoff K, Tsai JS, Strafaci JA, Freedman ML. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp. Neurol, 150: 40-44, 2003.
91. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72: 971-983, 1993
92. Benchoua A, Trioulier Y, Zala D, Gaillard MC, Lefort N, Dufour N, Saudou F, Elalouf JM, Hirsch E, Hantraye P, Deglon N, Brouillet E. Involvement of mitochondrial complex II defects inneuronal death produced by N-terminus fragment of mutated huntingtin. Mol. Biol. Cell, 17: 1652-1663, 2006.
93. Goffredo D, Rigamonti D, Zuccato C, Tartari M, Valenza M, Cattaneo E. Prevention of cytosolic IAPs degradation: a potential pharmacological target in Huntington's Disease. Pharmacol. Res, 52: 140-150, 2005.
94. Bae BI, Xu H, Igarashi S, Fujimuro M, Agrawal N, Taya Y, Hayward SD, Moran TH, Montell C, Ross CA, Snyder SH, Sawa A. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron, 47: 29-41, 2005.
95. Rigamonti D, Sipione S, Goffredo D, Zuccato C, Fossale E, Cattaneo E. Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J. Biol. Chem, 276: 14545-14548, 2001.
96. Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, Frey AS, Menon AS, Li XJ, Stieg PE, Yuan J, Penney JB, Young AB, Cha JH, Friedlander RM. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature, 399: 263-267, 1999.
97. Kiechle T, Dedeoglu A, Kubilus J, Kowall NW, Beal MF, Friedlander RM, Hersch SM, Ferrante RJ. Cytochrome C and caspase-9 expression in Huntington's disease. Neuromolec. Med, 1: 183-195, 2002.
98. Sanchez I, Xu CJ, Juo P, Kakizaka A, Blenis J, Yuan J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron, 22: 623-633, 1999.
99. Shi P, Gal J, l Kwinter DM, Liu X, Zhu H. Mitochondrial dysfunction in amyotrophic laterasclerosis. Biochim. Biophys. Acta, 1802:45-51, 2010.
100. Biessels GJ, Kamal A, Ramakers GM, Urban IJ, Spruijt BM, Erkelens DW, Gispen WH. Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes, 45: 1259-1266, 1996.
101. Biessels GJ, Gispen WH. The impact of diabetes on cognition: what can be learned from rodent models? Neurobiol. Aging, 26 Suppl 1:36-41, 2005.
102. Li ZG, Sima AA. C-peptide and central nervous system complications in diabetes. Exp. Diabesity Res, 5: 79-90, 2004.
103. Li ZG, Zhang W, Sima AA. The role of impaired insulin/IGF action in primary diabetic encephalopathy. Brain Res, 1037: 12-24, 2005.
104. Makimattila S, Malmberg-Ceder K, Hakkinen AM, Vuori K, Salonen O, Summanen P, Yki-Jarvinen H, Kaste M, Heikkinen S, Lundbom N, Roine RO. Brain metabolic alterations in patients with type 1 diabetes-hyperglycemia-induced injury. J. Cereb. Blood Flow Metab, 4:1393-1399, 2004.
105. Wessels AM, Simsek S, Remijnse PL, Veltman DJ, Biessels GJ, Barkhof F, Scheltens P, Snoek FJ, Heine RJ, Rombouts SA. Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. Diabetologia, 49: 2474-2480, 2006.
106. Brands AM, Biessels GJ, de Haan EH, Kappelle LJ, Kessels RP. The effects of type 1 diabetes on cognitive performance: a metaanalysis. Diabetes Care, 28:726-735, 2005
107. Ryan CM. Neurobehavioral complications of type I diabetes. Examination of possible risk factors. Diabetes Care, 11: 86-93, 1988.
108. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J. Mol. Med, 82: 510-529, 2004.